NCT04708418 2026-03-18
A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
27 trialsNCT05710328 2026-03-02
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT02125786 2026-02-24
A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT01946529 2026-02-23
Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT05451290 2026-02-12
Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer
First Affiliated Hospital of Zhejiang University
Phase 2 Active not recruiting
NCT05826509 2026-01-15
SUGAR
Institut Claudius Regaud
Phase 2 Active not recruiting
NCT06660810 2026-01-15
Neoadjuvant Intralesional Injection of Talimogene Laherparepvec
University of Iowa
Phase 2 Active not recruiting
NCT07339488 2026-01-14
ILDR-03
Shantou University Medical College
Phase 2 Active not recruiting
NCT00929214 2025-12-17
Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01871766 2025-12-17
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT01723774 2025-12-09
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
Washington University School of Medicine
Phase 2 Active not recruiting
NCT05882513 2025-12-02
Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Active not recruiting
NCT02792582 2025-11-12
A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT03978624 2025-10-15
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT03563248 2025-10-01
Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT06124378 2025-09-24
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
First Affiliated Hospital of Guangxi Medical University
Phase 2 Active not recruiting
NCT02981940 2025-09-02
A Study of Abemaciclib in Recurrent Glioblastoma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04062708 2025-07-08
CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
Alliance Foundation Trials, LLC.
Phase 2 Active not recruiting
NCT01753414 2025-01-06
POSTILV
Radiation Therapy Oncology Group
Phase 2 Active not recruiting
NCT01553942 2024-11-20
Afatinib With CT and RT for EGFR-Mutant NSCLC
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT05724329 2024-09-19
Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Active not recruiting
NCT02641093 2024-08-29
Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma
University of Cincinnati
Phase 2 Active not recruiting
NCT04997941 2024-04-23
MORE-T
Seoul National University Hospital
Phase 2 Active not recruiting
NCT03840239 2023-10-25
TESS
Sun Yat-sen University
Phase 2 Active not recruiting
NCT02676349 2023-09-28
Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)
Institut de Cancérologie de Lorraine
Phase 2 Active not recruiting
NCT05602935 2023-09-28
Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study
The Second Affiliated Hospital of Fujian Medical University
Phase 2 Active not recruiting
NCT04398914 2022-03-31
Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
Shanghai Jiao Tong University School of Medicine
Phase 2 Active not recruiting